Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29668334 | 1.00 | IKBKB (0.47) | IKBKBSCN9AMGAMALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL14843117 | 0.98 | IKBKB (0.46) | IKBKBSCN9AMGAMALDH1A1MAPT | |
| SCHEMBL27808756 | 0.98 | IKBKB (0.46) | IKBKBSCN9AMGAMALDH1A1MAPT | |
| Pyridine SCHEMBL17099679 | 0.90 | IKBKB (0.41) | IKBKBSCN9AMGAMALDH1A1KDM4E | |
| Azetidine SCHEMBL8511575 | 0.90 | IKBKB (0.41) | IKBKBSCN9AMGAMALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL14844844 | 0.89 | IKBKB (0.40) | IKBKBSCN9AMGAMALDH1A1MAPT | |
| SCHEMBL28088528 | 0.87 | IKBKB (0.39) | IKBKBSCN9AMGAMALDH1A1MAPT | |
| SCHEMBL10559629 | 0.85 | IKBKB (0.41) | IKBKBMGAMALDH1A1MAPTGAA | |
| SCHEMBL2915555 | 0.83 | IKBKB (0.38) | IKBKBSCN9AMGAMALDH1A1MAPT | |
| SCHEMBL29427872 | 0.82 | MGAM (0.50) | MGAMALDH1A1MAPTKDM4EGPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053799-A1 | COMPOUNDS FOR TREATING CANCER | EVEXTA BIO (FR) | 2026-02-26 | — | — | US | claimed |
| EP-4568662-A1 | COMPOUNDS FOR TREATING CANCER | Evexta Bio (FR) | 2025-06-18 | — | — | EP | claimed |
| CN-119997942-A | Compounds for the treatment of cancer | 埃维克斯塔生物公司 | 2025-05-13 | — | — | CN | claimed |
| WO-2024033513-A1 | COMPOUNDS FOR TREATING CANCER | DIACCURATE (FR) | 2024-02-15 | — | — | WO | claimed |
| CN-115197225-B | Five-membered heterocyclic quinazolinone compound and preparation method thereof | 贵州大学 | 2023-04-11 | — | — | CN | claimed |
| CN-115806550-A | Bicyclic BET bromodomain inhibitors and uses thereof | 康威基内有限公司 | 2023-03-17 | — | — | CN | claimed |
| CN-110981817-B | Quinazoline amide compound and application thereof | 青岛科技大学 | 2022-09-16 | — | — | CN | claimed |
| EP-3810596-A1 | QUINOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2021-04-28 | — | — | EP | claimed |
| CN-110981817-A | Quinazoline amide compound and application thereof | 青岛科技大学 | 2020-04-10 | — | — | CN | claimed |
| CN-109641886-A | bicyclic BET bromodomain inhibitors and uses thereof | 康威基内有限公司 | 2019-04-16 | — | — | CN | claimed |
| CN-103797002-B | Dyrk1 inhibitors and uses thereof | 迪亚克森海特公司 | 2017-02-22 | — | — | CN | claimed |
| CN-103797002-A | Dyrk1 inhibitors and uses thereof | EXONHIT SA | 2014-05-14 | — | — | CN | claimed |
| EP-0094080-B1 | PYRIDO(2,1-B)QUINAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1987-09-09 | — | — | EP | claimed |
| WO-2026075985-A1 | QUINOLINE- AND QUINAZOLINE-CARBOXAMIDE DERIVATIVES AS CD38 INHIBITORS | NEOLAIA INC. (US) | 2026-04-09 | — | — | WO | disclosed |
| US-20260053799-A1 | COMPOUNDS FOR TREATING CANCER | EVEXTA BIO (FR) | 2026-02-26 | — | — | US | disclosed |
| US-20260053799-A1 | COMPOUNDS FOR TREATING CANCER | EVEXTA BIO (FR) | 2026-02-26 | — | — | US | disclosed |
| EP-1228039-A1 | N-GUANIDINOALKYLAMIDES, THEIR PREPARATION, THEIR USE, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032611-A1 | N-GUANIDINOALKYLAMIDES, THEIR PREPARATION, THEIR USE, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-05-10 | — | — | WO | disclosed |
| EP-1095933-A1 | Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them | Aventis Pharma Deutschland GmbH (DE) | 2001-05-02 | — | — | EP | disclosed |
| EP-0094080-B1 | PYRIDO(2,1-B)QUINAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053799-A1 | COMPOUNDS FOR TREATING CANCER | NCOA1, AR, ESR2 | IKBKB 1562/4885SCN9A 215/4885MGAM 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.